LEADER 02360nam  2200565   450 
001 9910792287203321
005 20230803024235.0
010   $a1-78084-309-7
035   $a(CKB)2560000000152104
035   $a(EBL)1179627
035   $a(SSID)ssj0001599919
035   $a(PQKBManifestationID)16306842
035   $a(PQKBTitleCode)TC0001599919
035   $a(PQKBWorkID)14892848
035   $a(PQKB)11518884
035   $a(MiAaPQ)EBC1179627
035   $a(Au-PeEL)EBL1179627
035   $a(OCoLC)876507114
035   $a(EXLCZ)992560000000152104
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAdvances in the management of pulmonary arterial hypertension /$feditors, Kimberly A. Smith, Dustin R. Fraidenburg, Jason X.-J. Yuan
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (129 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-311-9 
327   $aTitle page; Copyright page; Contents; Foreword. Current therapies for the treatment of pulmonary arterial hypertension; 1. Etiology and prevalence of pulmonary arterial hypertension; 2. Pathology and diagnosis of pulmonary arterial hypertension; 3. Conventional therapy; 4. Targeted therapies: prostaglandins; 5. Targeted therapies: endothelin receptor antagonists ; 6. Stimulators and activators of soluble guanylate cyclase: potential therapeutic indications; 7. Surgical approaches in pulmonary arterial hypertension; 8. Monitoring and prognosis of pulmonary arterial hypertension
327   $a9. Right ventricular failureIndex
330   $aAdvances in the Management of Pulmonary Arterial Hypertension
606   $aPulmonary hypertension
606   $aPulmonary hypertension$xTreatment
615  0$aPulmonary hypertension.
615  0$aPulmonary hypertension$xTreatment.
676   $a616.24
702   $aYuan$b Jason X.-J.$f1963-
702   $aFraidenburg$b Dustin R.
702   $aSmith$b Kimberly A.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910792287203321
996   $aAdvances in the management of pulmonary arterial hypertension$93851818
997   $aUNINA